Impact and prevention of severe exacerbations of COPD: a review of the evidence.

2.50
Hdl Handle:
http://hdl.handle.net/11287/620510
Title:
Impact and prevention of severe exacerbations of COPD: a review of the evidence.
Authors:
Halpin, David M; Miravitlles, M.; Metzdorf, N.; Celli, B.
Abstract:
Severe exacerbations of COPD, ie, those leading to hospitalization, have profound clinical implications for patients and significant economic consequences for society. The prevalence and burden of severe COPD exacerbations remain high, despite recognition of the importance of exacerbation prevention and the availability of new treatment options. Severe COPD exacerbations are associated with high mortality, have negative impact on quality of life, are linked to cardiovascular complications, and are a significant burden on the health-care system. This review identified risk factors that contribute to the development of severe exacerbations, treatment options (bronchodilators, antibiotics, corticosteroids [CSs], oxygen therapy, and ventilator support) to manage severe exacerbations, and strategies to prevent readmission to hospital. Risk factors that are amenable to change have been highlighted. A number of bronchodilators have demonstrated successful reduction in risk of severe exacerbations, including long-acting muscarinic antagonist or long-acting β2-agonist mono- or combination therapies, in addition to vaccination, mucolytic and antibiotic therapy, and nonpharmacological interventions, such as pulmonary rehabilitation. Recognition of the importance of severe exacerbations is an essential step in improving outcomes for patients with COPD. Evidence-based approaches to prevent and manage severe exacerbations should be implemented as part of targeted strategies for disease management.
Citation:
Impact and prevention of severe exacerbations of COPD: a review of the evidence. 2017, 12:2891-2908 Int J Chron Obstruct Pulmon Dis
Publisher:
Dove Press
Journal:
International journal of chronic obstructive pulmonary disease
Issue Date:
Oct-2017
URI:
http://hdl.handle.net/11287/620510
DOI:
10.2147/COPD.S139470
PubMed ID:
29062228
Additional Links:
https://dx.doi.org/10.2147/COPD.S139470
Note:
This article is freely available via Open Access. Click on the Additional Link above to access the full-text via the publisher's site.
Type:
Journal Article
Language:
en
ISSN:
1178-2005
Appears in Collections:
Respiratory Medicine; 2017 RD&E publications

Full metadata record

DC FieldValue Language
dc.contributor.authorHalpin, David Men
dc.contributor.authorMiravitlles, M.en
dc.contributor.authorMetzdorf, N.en
dc.contributor.authorCelli, B.en
dc.date.accessioned2017-11-15T14:20:20Z-
dc.date.available2017-11-15T14:20:20Z-
dc.date.issued2017-10-
dc.identifier.citationImpact and prevention of severe exacerbations of COPD: a review of the evidence. 2017, 12:2891-2908 Int J Chron Obstruct Pulmon Disen
dc.identifier.issn1178-2005-
dc.identifier.pmid29062228-
dc.identifier.doi10.2147/COPD.S139470-
dc.identifier.urihttp://hdl.handle.net/11287/620510-
dc.description.abstractSevere exacerbations of COPD, ie, those leading to hospitalization, have profound clinical implications for patients and significant economic consequences for society. The prevalence and burden of severe COPD exacerbations remain high, despite recognition of the importance of exacerbation prevention and the availability of new treatment options. Severe COPD exacerbations are associated with high mortality, have negative impact on quality of life, are linked to cardiovascular complications, and are a significant burden on the health-care system. This review identified risk factors that contribute to the development of severe exacerbations, treatment options (bronchodilators, antibiotics, corticosteroids [CSs], oxygen therapy, and ventilator support) to manage severe exacerbations, and strategies to prevent readmission to hospital. Risk factors that are amenable to change have been highlighted. A number of bronchodilators have demonstrated successful reduction in risk of severe exacerbations, including long-acting muscarinic antagonist or long-acting β2-agonist mono- or combination therapies, in addition to vaccination, mucolytic and antibiotic therapy, and nonpharmacological interventions, such as pulmonary rehabilitation. Recognition of the importance of severe exacerbations is an essential step in improving outcomes for patients with COPD. Evidence-based approaches to prevent and manage severe exacerbations should be implemented as part of targeted strategies for disease management.en
dc.language.isoenen
dc.publisherDove Pressen
dc.relation.urlhttps://dx.doi.org/10.2147/COPD.S139470en
dc.rightsArchived with thanks to International journal of chronic obstructive pulmonary disease. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.en
dc.subjectWessex Classification Subject Headings::Respiratory medicineen
dc.titleImpact and prevention of severe exacerbations of COPD: a review of the evidence.en
dc.typeJournal Articleen
dc.identifier.journalInternational journal of chronic obstructive pulmonary diseaseen
dc.description.noteThis article is freely available via Open Access. Click on the Additional Link above to access the full-text via the publisher's site.en
dc.type.versionPublisheden

Related articles on PubMed

All Items in RD&E Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.